Bogda Koczwara, Director of Australian Research Centre for Cancer Survivorship, shared on LinkedIn:
“A very important study, just published in Journal of Clinical Oncology Oncology Practice.
A global, propensity-matched cohort study (over 30,000 patients) examining rates of CVD MACE hospitalisations in people treated with immunotherapy vs historical chemotherapy controls.
- Higher risks with immunotherapy (RR 1.4) – consistent across hearth failure, stroke and myocardial infarction. Risk varied with type of immunotherapy.
- Proactive management of this risk is key component of good cancer treatment.
If you want tips on how to do it – read.”
Title: Prevention and management of cardiovascular disease in adults with cancer: an International Cardio-Oncology Society (IC-OS) and Multinational Association of Supportive Care in Cancer (MASCC) clinical practice statement
Authors: Susan Dent, Michelle B. Nadler, Anne Blaes, Ahamed Iqbal, Hannah Naa Gogwe Ayettey, Jose Alvarez-Cardona, Alexandre Chan, Eng-Siew Koh, Raul Cordoba Mascunano, Mridula George, Naa Adorkor Aryeetey, Erin J. Howden, Sase Kazuhiro, Nida Latif, Aya F. Ozaki, Cherith J. Semple, Sivatharshini Ramalingam, Neil M. Iyenger, Hope S. Rugo, Bogda Koczwara
Read the full article.
You may also find this interesting:
